Physician profile
Mark Hesselrode
NPI 1164417127
$8,819.48
in general payments reported to CMS, 2019-2025
23 companies · $2,031 in 2025
The $2,031 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $975 · 2022: $1,759 · 2023: $1,915 · 2024: $2,140 · 2025: $2,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,085.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,510.86 | 2021-2025 | |
| Alkermes, INC. | $1,328.10 | 2021-2025 | Lybalvi, Aristada |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,007.10 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $919.38 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $899.10 | 2021-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $646.89 | 2024-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $440.34 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $407.37 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $281.50 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $237.50 | 2022-2025 | Qelbree, Qelbree |
| Corium, LLC | $215.66 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $208.58 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $205.40 | 2023-2024 | Quviviq |
| Tris Pharma INC | $204.75 | 2022-2024 | Dyanavel Xr |
| Bausch Health US, LLC | $110.43 | 2021-2023 | Aplenzin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $53.98 | 2023 | Austedo, Austedo Xr |
| Almatica Pharma LLC | $30.24 | 2024 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $24.99 | 2021 | |
| Collegium Pharmaceutical, INC. | $20.51 | 2025 | Jornay Pm |
| Eisai INC. | $19.44 | 2021 | |
| Neurocrine Biosciences, INC. | $18.62 | 2025 | |
| Avanir Pharmaceuticals, INC. | $15.57 | 2022 | |
| Noven Therapeutics, LLC | $13.17 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hesselrode listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.